Nucs AI Strengthens Leadership to Enhance Precision in Prostate Cancer Treatment

Nucs AI, a pioneering company in the realm of AI-driven radiology solutions specifically tailored for prostate cancer, has made headlines with the recent expansion of its leadership team. This move features the appointment of three key individuals: Andrew Findley as Chief of Staff, Dr. Jayashri Pawar as Medical Director, and Will Plogger as Vice President of Product. These appointments aim to amplify the company's mission of revolutionizing prostate cancer diagnostics and treatment through advanced AI technologies.

The newly formed leadership team blends substantial clinical expertise with AI innovation and a wealth of experience in product scaling. Leading these efforts are Nucs AI co-founders: CEO Nijat Ahmadov and CTO Farid Yagubbayli.

Meeting the Challenge in Oncology
As the healthcare industry grapples with the complexities of oncology, particularly prostate cancer, the need for reliable diagnostics is more pressing than ever. The company's platform seeks to address major hurdles faced in the field, including the fact that over half of patients suffering from advanced prostate cancer are not deriving benefits from widely-utilized radioligand therapies. To tackle these challenges, Nucs AI's technology aims to provide enhanced clarity and standardized, actionable insights for clinicians.

New Leadership Appointments

Andrew Findley, Chief of Staff

Andrew Findley joins Nucs AI with a solid background in healthcare technology and consulting. Previously, he played a pivotal role at Lyra Health where he oversaw go-to-market strategies and operations, significantly enhancing access to mental health services for large employers. His journey in the healthcare sphere is deeply personal, shaped by his family experiences with cancer, instilling in him a strong commitment to improving cancer care outcomes.

Dr. Jayashri Pawar, Medical Director

Bringing a wealth of experience in clinical radiology, including specialized knowledge in sectors such as oncology and neuroradiology, Dr. Pawar’s role is crucial in ensuring that Nucs AI’s offerings resonate with the real demands of patient care. Her extensive research background, including significant publications in prestigious journals, positions her as a key figure in refining Nucs AI’s AI models and securing their clinical validation.

Will Plogger, Vice President of Product

Will Plogger, previously a significant player at Imagen Technologies, joins Nucs AI with a record of scaling AI products within medical imaging. His passion for cancer care stems from personal experience, as he has been directly impacted by his mother's battle with breast cancer. Will is set to lead product development, ensuring it aligns with patient needs and seamlessly integrates into clinical practice.

In addition to the boosted executive team, Nucs AI is actively forming a prestigious Medical Advisory Board. This group will consist of leading clinicians and researchers in oncology and radiology, facilitating the alignment of Nucs AI’s solutions with real-world practices and clinical validation standards.

Aiming for the Future

CEO Nijat Ahmadov articulated the company's ambitious goal: ‘Nucs AI is tackling one of the most complex challenges in oncology—bringing consistency, speed, and predictive insight to prostate cancer imaging. With our new executive team, we are enhancing every facet of AI research, clinical application, and market adoption.’

CTO Farid Yagubbayli complemented this by expressing the unique combination of skills and experiences within the team. Their firsthand experiences in radiology convey a profound understanding that informs their innovative solutions, aiming to bridge the gap between technological development and practical healthcare impact.

As momentum builds, Nucs AI is progressing with a robust pipeline of AI solutions, cementing partnerships with notable research institutions and clinical trial sponsors. The company is steadily moving toward regulatory approvals and wider implementation within care environments, pushing the boundaries of what is possible in precision oncology.

About Nucs AI

Nucs AI is committed to redefining cancer care through AI-enhanced imaging and predictive analytics. Their product suite—including DeepPSMA, SelectPSMA, and TrackPSMA—focuses on automating critical processes such as detection, staging, and treatment evaluation of prostate cancer. Collaborations with prestigious institutions like Johns Hopkins exemplify Nucs AI's commitment to advancing molecular imaging and setting new benchmarks for AI-assisted diagnostics.